YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Pfizer and BIND Therapeutics Sign Nanotech Drug Deal

April 3, 2013 | BIND Therapeutics (recently rechristened from BIND Biosciences) has signed a $160 million per drug collaboration with Pfizer to develop targeted medicines with nanotechnology. BIND is developing an experimental group of targeted, programmable medicines called Accurins to treat cancer, heart disease, and inflammatory disorders. Boston Globe
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.